Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resectable NSCLC × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 556 Carcinoma, Non-Small-Cell Lung 505 Prostatic Neoplasms 327 Multiple Myeloma 271 Neoplasms 263 Colorectal Neoplasms 258 Leukemia, Myeloid, Acute 226 Squamous Cell Carcinoma of Head and Neck 216 Lung Neoplasms 209 Neoplasm Metastasis 207 Carcinoma, Hepatocellular 197 Pancreatic Neoplasms 178 Melanoma 175 Triple Negative Breast Neoplasms 173 Recurrence 151 Ovarian Neoplasms 149 Lymphoma 143 Glioblastoma 135 Brain Neoplasms 133 Leukemia, Lymphocytic, Chronic, B-Cell 130 Sarcoma 127 Stomach Neoplasms 125 Carcinoma, Renal Cell 123 Lymphoma, Large B-Cell, Diffuse 122 Head and Neck Neoplasms 117 Precursor Cell Lymphoblastic Leukemia-Lymphoma 115 Myelodysplastic Syndromes 110 Rectal Neoplasms 105 Uterine Cervical Neoplasms 101 Lymphoma, Non-Hodgkin 98

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡